Akebia (NASDAQ: AKBA) legal chief details stock and option holdings in Form 3

Rhea-AI Filing Summary

Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company. She reports beneficial ownership of multiple blocks of Akebia common stock, including 171,816 shares held directly and additional shares linked to restricted stock unit grants.

The filing also lists several employee stock options to buy Akebia common stock, with exercise prices ranging from $0.63 to $2.88 per share and expiration dates between 2031 and 2035. These options generally vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rucci Carolyn M.

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/26/2026

3. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	171,816	D
Common Stock	36,800(1)	D
Common Stock	99,534(2)	D
Common Stock	160,000(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(3)	09/30/2031	Common Stock	61,000	$2.88	D
Employee Stock Option (right to buy)	(4)	02/28/2032	Common Stock	27,900	$2.16	D
Employee Stock Option (right to buy)	(4)	01/31/2033	Common Stock	165,600	$0.63	D
Employee Stock Option (right to buy)	(5)	01/31/2034	Common Stock	224,000	$1.68	D
Employee Stock Option (right to buy)	(5)	01/31/2035	Common Stock	240,000	$2.24	D

Explanation of Responses:

1. The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. All of the restricted stock units will vest on January 31, 2026, subject to the reporting person's continued service with the Issuer on such vesting date.

2. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

3. The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

4. The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

5. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Remarks:

	/s/ Carolyn M. Rucci	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Akebia Therapeutics (AKBA) Form 3 for Carolyn M. Rucci show?

The Form 3 shows Carolyn M. Rucci’s initial beneficial ownership of Akebia common stock and employee stock options. It details several common stock positions and option grants, including holdings tied to the company’s 2014 and 2023 equity incentive plans with specified vesting schedules.

How many Akebia (AKBA) common shares does Carolyn M. Rucci directly report on Form 3?

Carolyn M. Rucci reports 171,816 Akebia common shares held directly. The filing also lists additional common stock entries, including amounts of 36,800, 99,534 and 160,000 shares, which are associated with restricted stock unit grants subject to specific vesting conditions under company equity plans.

What stock option grants for Akebia (AKBA) are disclosed for Carolyn M. Rucci?

The filing lists several employee stock options to buy Akebia common stock: 61,000 shares at $2.88, 27,900 at $2.16, 165,600 at $0.63, 224,000 at $1.68, and 240,000 at $2.24, each with specified future expiration dates between 2031 and 2035.

How do Carolyn M. Rucci’s Akebia (AKBA) equity awards vest according to the Form 3?

Restricted stock units under the 2014 plan vest fully on January 31, 2026, while units under the 2023 plan vest one-third on each of the first three anniversaries of the grant date. Most option grants vest 25% after one year, then quarterly over the following three years.

What is the inducement stock option grant disclosed for Akebia (AKBA) SVP Carolyn M. Rucci?

One option grant was awarded as an inducement material to her employment under Nasdaq Listing Rule 5635(c)(4). This grant vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal quarterly installments, subject to continued service.

Does the Akebia (AKBA) Form 3 for Carolyn M. Rucci report any stock sales or purchases?

The Form 3 functions as an initial ownership report and lists existing common stock and option holdings. It describes restricted stock units and stock options with future vesting and expiration terms rather than recording new open-market stock sales or purchases by Carolyn M. Rucci.